参考文献/References:
[1]Cuixue W,Jiedong Z,Jinquan W,et al.Progress in the mechanism and targeted drug therapy for COPD[J].Signal Transduct Target Ther,2020,5(1):248.[2]Peng G,Rui L,Tiehua P,et al.Pathological Mechanism and T argeted Drugs ofCOPD[J].Int J Chron Obstruct Pulmon Dis,2022,12(17):1565-1575.[3]David MGH,Gerard JC,Alberto P,et al.Global initiative for the diagnosis,management,and prevention of chronic obstructive lung disease.The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2021,203(1):24-36.[4]GBD 2017 Causes of Death Collaborators.Global,regional,and national age-sex-specific mor-tality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the Global burden of disease study 2017[J].Lancet,2018,392(10159):1736-1788.[5]Chen W,Jianying X,Lan Y,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study):a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.[6]Mairi M,Alberto P,MarcoC,et al.Chronic obstructive pulmonary disease exacerbation fundamentals:diagnosis,treatment,prevention and disease impact [J].Respirology,2021,26(6):532-551.[7]Wedzicha JA,Miravitlles M,Hurst JR,et al.Management of COPD exacerbations:a European Respiratory Society/American Thoracic Society guideline[J].Eur Respir J,2017,49(3):1600791.[8]Morasert T,Jantarapootirat M,Phinyo P,et al.Prognostic indicators for in-hospital mortality in COPD with acute exacerbation in Thailand:a retrospective cohort study[J].BMJ Open Respir Res,2020,7(1):e000488.[9]Nagihan Durmus K,Gulsah S,Ulku Aka A,et al.Serum Uric Acid Levels and Uric Acid/Creatinine Ratios in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients: Are These Parameters Efficient Predictors of Patients at Risk for Exacerbation and/or Severity of Disease?[J].Med Sci Monit,2016,22:4169-4176.[10]Rumora L,Hlapcic I,Popovic- Grle S,et al.Uric acid and uric acid to creatinine ratio in the assessment of chronic obstructive pulmonary disease: Potential biomarkers in multicom-ponent models comprising IL- 1beta[J].PLoS One,2020,15(6):e0234363.[11]Kir E,Güven Atici A,Güllü YT,et al.The relationship between serum uric acid level and uric acid/creatinine ratio with chronic obstructive pulmonary disease severity (stable or acute exacerbation) and the development of cor pulmonale[J].Int J Clin Pract,2021,75(8):e14303.[12]Polverino F,Laucho-Contreras ME,Petersen H,et al.A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med，2017，195(11):1464-1476.[13]Romundstad S,Naustdal T,Romundstad PR,et al.COPD and microalbuminuria: a 12-year follow-up study[J].Eur Respir J,2014,43(4):1042-1050.[14]Gupta KK,Kotwal M,Atam V,et al.Study of microalbuminuria in chronic obstructive pulmonary disease patients at tertiary care teaching hospital[J].J Family Med Prim Care,2020,9(8):3916-3920.[15]Susanne L,John W,Marianne H,et al.Urinary albumin excretion:A predictor of risk of cardiovascular disease:A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men[J].Am J Hypertens,1996,9(8):770-778.[16]Agrawal A,Garg R,Sahu D,et al.Study the association of chronic obstructive pulmonary disease with early endothelial dysfunction and its impact on cardiovascular system by estimating urinary albumin creatinine ratio[J].Lung India,2017,34(2):138-143.[17]Zhang WZ,Rice MC,Hoffman KL,et al.Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort[J].JCI Insight,2020,5(3):e133984.[18]张净,王珊,石赟,等.血清胱抑素C、尿白蛋白肌酐比值在老年COPD合并肾损伤早期诊断中的价值[J].河北医药,2021,43(19):2983-2985.[19]Patel SS,Molnar MZ,Tayek JA,et al.Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature[J].J Cachexia Sarco-penia Muscle,2013,4(1):19-29.[20]Telo S,Kulu?觟ztürk M,Deveci F,et al.Serum Cystatin C Levels in COPD: Potential Diagnostic Value and Relation between Respiratory Functions[J].J Med Biochem,2018,37(4):434-440.[21]Chai L,Feng W,Zhai C,et al.The association between cystatin C and COPD: a meta-analysis and systematic review[J].BMC Pulm Med,2020,20(1):182.[22]Kashani KB,Frazee EN,Kukrálová L,et al.Evalu-ating Muscle Mass by Using Markers of Kid-ney Function: Development of the Sarcopenia Index[J].Crit Care Med,2017,45(1):e23-e29.[23]Amado CA,García-Unzueta MT,Lavin BA,et al.The ratio serum creatinine/serum cystatin C(a surrogate marker of musclemass)as a predictor of hospitalization in chronic obstructive pulmonary disease outpatients[J].Respiration,2019,97(4):302-309.[24]Nishiki K,Nojiri M,Kato R,et al.Serum Creatinine/Cystatin C Ratio Associated with Cross-Sectional Area of Erector Spinae Muscles and Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease[J].Int J Chron Obstruct Pulmon Dis,2021,16:3513-3524.[25]Hirai K,Tanaka A,Homma T,et al.Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease[J].Clin Nutr,2021,40(3):1274-1280.[26]Chen Z,Zha L,Ma X,et al.Serum Creatinine/Cystatin C Ratio as a Predictor of In-hospital Mortality in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Lung,2022,200(5):609-617.[27]Lochner M,Berod L,Sparwasser T.Fatty acid metabolism in the regulation of T cell function[J].Trends Immunol,2015,36(2):81-91.[28]Stanislav K,Anna K.Anti-Inflammatory Function of Fatty Acids and Involvement of Their Metabolites in the Resolution of Inflammation in Chronic Obstructive Pulmonary Disease[J].Int J Mol Sci,2021,22(23):12803.[29]Chen H,Li Z,Dong L,et al.Lipid metabolism in chronic obstructive pulmonary disease[J].Int J Chron Obstruct Pulmon Dis,2019,14:1009-1018.[30]Kotlyarov S.High-Density Lipoproteins: A Role in Inflammation in COPD[J].Int J Mol Sci,2022,23(15):8128.[31]胡萍,王娟,张运剑.慢性阻塞性肺疾病患者同型半胱氨酸及血脂水平分析[J].中华全科医学,2017,15(10):1711-1713,1751.[32]戚春辉,丁奇龙,杨勇.血浆总胆固醇降低对住院AECOPD患者临床预后的评估[J].中国医药导刊,2017,19(6):541-542,544.[33]Ben Anes A,Ben Nasr H,Tabka Z,et al.Plasma Lipid Profiling Identifies Phosphatidylcholine 34:3 and Triglyceride 52:3 as Potential Markers Associated with Disease Severity and Oxidative Status in Chronic Obstructive Pulmonary Disease[J].Lung,2022,200(4):495-503.[34]Rohatgi A.High-density lipoprotein function measurement in human studies:focus on cholesterol efflux capacity[J].Prog Cardiovasc Dis,2015,58(1):32-40.[35]Gunay S,Sariaydin M,Acay A.New Predictor of Atherosclerosis in Subjects With COPD: Atherogenic Indices[J].Respir Care,2016,61(11):1481-1487.[36]Chen H,Xiong C,Shao X,et al.Lymphocyte To High-Density Lipoprotein Ratio As A New Indicator Of Inflammation And Metabolic Syndrome[J].Diabetes Metab Syndr Obes,2019,12:2117-2123.[37]Huang Y,Ding K,Dai Z,et al.The Relationship of Low-Density-Lipoprotein to Lymphocyte Ratio with Chronic Obstructive Pulmonary Disease[J].Int J Chron Obstruct Pulmon Dis,2022,17:2175-2185.[38]Shen Y,Yang T,Guo S,et al.Increased serum ox-LDL levels correlated with lung function, inflammation, and oxidative stress in COPD[J].Mediators Inflamm,2013,2013:972347.[39]Zafirova-Ivanovska B,Stojkovikj J,Dokikj D,et al.The Level of Cholesterol in COPD Patients with Severe and Very Severe Stage of the Disease[J].Open Access Maced J Med Sci,2016,4(2):277-282.
相似文献/References:
[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]刘 静.冠状动脉粥样硬化性心脏病合并糖尿病的血脂检验结果分析[J].医学信息,2018,31(04):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
LIU Jing.Analysis of Blood Lipid Test Results in Coronary Atherosclerotic Heart Disease Complicated with Diabetes Mellitus[J].Journal of Medical Information,2018,31(23):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
[4]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(23):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[5]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[6]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[7]罗 倩.COPD加重期患者肺功能、血气指标及
炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(23):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[8]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病
引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(23):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[9]朱 玉,戴 夫,彭 琼.胃肠息肉患者血脂水平影响因素及相关性分析[J].医学信息,2019,32(02):79.[doi:10.3969/j.issn.1006-1959.2019.02.023]
ZHU Yu,DAI Fu,PENG Qiong.Influential Factors and Correlation Analysis of Blood Lipid Levels in Patients with Gastrointestinal Polyps[J].Journal of Medical Information,2019,32(23):79.[doi:10.3969/j.issn.1006-1959.2019.02.023]
[10]金彦青.NPPV治疗慢性阻塞性肺疾病合并
重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(23):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]